Press Releases April 28, 2026 04:05 PM

iRhythm Holdings to Present at the Bank of America Securities 2026 Health Care Conference

iRhythm Holdings to Present at Bank of America Securities 2026 Health Care Conference

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
IRTC

iRhythm Holdings, a digital health care company specializing in wearable biosensors and advanced data analytics for disease detection and prevention, announced it will present at the Bank of America Securities 2026 Health Care Conference on May 13, 2026. The presentation will be webcast for investors and interested parties.

iRhythm Holdings to Present at the Bank of America Securities 2026 Health Care Conference
IRTC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • iRhythm is a leader in digital health care technology using wearable biosensors and proprietary algorithms to monitor heart health.
  • The company is presenting at a major industry event, signaling ongoing investor engagement and potential updates on business progress.
  • The webcast availability allows easy access for investors and stakeholders to learn about company developments.

SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2026 Health Care Conference.

iRhythm’s management is scheduled to present on Wednesday, May 13, 2026, 9:20 a.m. Pacific Time/12:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact
[email protected]

Media Contact
Kassandra Perry
[email protected]


Risks

  • The announcement does not provide new financial or operational updates, limiting immediate market impact.
  • Market reaction depends on the content of the upcoming presentation, which is not disclosed.
  • General market and sector volatility in the health care technology space can influence stock performance despite the presentation.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026